| Literature DB >> 28749967 |
Natalia Alencar de Pinho1, Raphael Coscas1,2, Marie Metzger1, Michel Labeeuw3, Carole Ayav4,5, Christian Jacquelinet6, Ziad A Massy1,7, Bénédicte Stengel1.
Abstract
Determinants of nonfunctional arteriovenous (AV) access, including timing of AV access creation, have not been sufficiently described. We studied 29 945 patients who had predialysis AV access placement and were included in the French REIN registry from 2005 through 2013. AV access was considered nonfunctional when dialysis began with a catheter. We estimated crude and adjusted odds ratio (OR) with 95% confidence intervals (CI) of nonfunctional versus functional AV access associated with case-mix, facility characteristics, and timing of AV access creation. Analyses were stratified by dialysis start condition (planned or as an emergency) and comorbidity profile. Overall, 18% patients had nonfunctional AV access at hemodialysis initiation. In the group with planned dialysis start, female gender (OR 1.43, 95% CI 1.32-1.56), diabetes (OR 1.28, 95% CI 1.15-1.44), and a higher number of cardiovascular comorbidities (OR 1.27, 95% CI 1.09-1.49, and 1.31, 1.05-1.64, for 3 and >3 cardiovascular comorbidities versus none, respectively) were independent predictors of nonfunctional AV access. A higher percentage of AV access creation at the region level was associated with a lower rate of nonfunctional AV access (OR 0.98, 95% CI 0.98-0.99 per 1% increase). The odds of nonfunctional AV access decreased as time from creation to hemodialysis initiation increased up to 3 months in nondiabetic patients with fewer than 2 cardiovascular comorbidities and 6 months in patients with diabetes or 2 or more such comorbidities. In conclusion, both patient characteristics and clinical practices may play a role in successful AV access use at hemodialysis initiation. Adjusting the timing of AV access creation to patients' comorbidity profiles may improve functional AV access rates.Entities:
Mesh:
Year: 2017 PMID: 28749967 PMCID: PMC5531527 DOI: 10.1371/journal.pone.0181254
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Cohort selection.
Abbreviations: AV, arteriovenous.
Cohort characteristics by arteriovenous access functionality status at hemodialysis initiation.
| Characteristics | Functional AV access | Nonfunctional AV access | Imputed missing data | |
|---|---|---|---|---|
| n = 24 486 (%) | n = 5459 (%) | (%) | ||
| 65.0 | 58.4 | <0.001 | 0 | |
| 70.5 (59.6–78.9) | 70.4 (58.4–78.6) | 0.145 | 0 | |
| <0.001 | 0 | |||
| Hypertensive/Vascular | 27.6 | 26.2 | ||
| Diabetic nephropathy | 23.3 | 30.9 | ||
| Glomerulonephritis | 12.4 | 8.9 | ||
| Polycystic kidney disease | 10.2 | 4.6 | ||
| Other | 16.5 | 17.9 | ||
| Unknown | 10.1 | 11.5 | ||
| 39.2 | 49.5 | <0.001 | 0.8 | |
| <0.001 | 5.1 | |||
| 0 | 47.7 | 40.3 | ||
| 1 | 25.8 | 26.1 | ||
| 2 | 15.3 | 17.6 | ||
| 3 | 7.9 | 10.9 | ||
| 4 or 5 | 3.3 | 5.2 | ||
| 1.3 | 2.9 | <0.001 | 5.1 | |
| 8.2 | 9.8 | <0.001 | 2.1 | |
| <0.001 | 11.1 | |||
| Autonomous | 87.9 | 79.5 | ||
| Needs assistance | 9.4 | 15.0 | ||
| Totally dependent | 2.7 | 5.5 | ||
| <0.001 | 19.9 | |||
| < 18.5 | 4.3 | 5.4 | ||
| [18.5–25.0] | 40.0 | 37.8 | ||
| [25.0–30.0] | 32.7 | 30.4 | ||
| ≥30.0 | 23.0 | 26.4 | ||
| 35.1 (5.7) | 32.5 (6.1) | <0.001 | 42.7 | |
| 10.6 (1.5) | 10.1 (1.6) | <0.001 | 16.7 | |
| 63.7 | 55.3 | <0.001 | 9.6 | |
| <0.001 | ||||
| eGFR≤5 | 7.8 | 12.8 | ||
| 5<eGFR≤10 | 54.9 | 52.9 | ||
| 10<eGFR≤15 | 29.1 | 25.6 | ||
| 15<eGFR≤20 | 6.5 | 6.5 | ||
| eGFR>20 | 1.7 | 2.2 | ||
| 9.6 | 37.2 | <0.001 | 2.2 | |
| <0.001 | 0 | |||
| In center | 92.2 | 97.0 | ||
| Satellite unit | 4.2 | 1.5 | ||
| Self-dialysis | 3.6 | 1.5 | ||
| <0.001 | 0 | |||
| Public university | 18.2 | 27.3 | ||
| Public non-university | 30.4 | 31.5 | ||
| Private for-profit | 31.8 | 30.3 | ||
| Private not-for-profit | 19.5 | 10.9 | ||
Abbreviations: AV, arteriovenous; IQR, interquartile range; SD, standard deviation; ESA, erythropoiesis-stimulating agents; MDRD, Modification of Diet in Renal Disease.
Determinants of nonfunctional arteriovenous access in patients with a planned dialysis start (n = 25 570).
| Variables | Crude OR (95% CI) | adjusted | ||
|---|---|---|---|---|
| 1.35 (1.25–1.45) | <0.001 | 1.43 (1.32–1.56) | <0.001 | |
| 1.01 (1.01–1.01) | 0.112 | 0.96 (0.96–0.97) | 0.035 | |
| <0.001 | <0.001 | |||
| Hypertensive/ Vascular | 1.37 (1.19–1.57) | 1.25 (1.07–1.47) | ||
| Diabetic nephropathy | 1.90 (1.66–2.18) | 1.33 (1.11–1.59) | ||
| Glomerulonephritis | 1 | 1 | ||
| Polycystic kidneys | 0.71 (0.59–0.86) | 1.01 (0.82–1.24) | ||
| Other | 1.52 (1.31–1.75) | 1.43 (1.21–1.68) | ||
| Unknown | 1.58 (1.35–1.85) | 1.35 (1.13–1.62) | ||
| 1.56 (1.45–1.67) | <0.001 | 1.28 (1.15–1.44) | <0.001 | |
| <0.001 | <0.001 | |||
| 0 | 1 | 1 | ||
| 1 | 1.21 (1.1–1.32) | 1.09 (0.98–1.21) | ||
| 2 | 1.27 (1.14–1.42) | 1.10 (0.97–1.25) | ||
| 3 | 1.48 (1.29–1.70) | 1.27 (1.09–1.49) | ||
| 4 or 5 | 1.67 (1.37–2.02) | 1.31 (1.05–1.64) | ||
| 2.21 (1.71–2.85) | <0.001 | 1.63 (1.21–2.20) | 0.006 | |
| 1.20 (1.06–1.36) | <0.001 | 1.13 (0.98–1.30) | 0.099 | |
| <0.001 | <0.001 | |||
| Autonomous | 1 | 1 | ||
| Needs assistance | 1.72 (1.53–1.93) | 1.33 (1.16–1.52) | ||
| Totally dependent | 2.08 (1.71–2.53) | 1.48 (1.19–1.85) | ||
| <0.001 | 0.034 | |||
| < 18.5 | 1.25 (1.02–1.53) | 1.09 (0.87–1.38) | ||
| [18.5–25.0] | 1 | |||
| [25.0–30.0] | 1.02 (0.93–1.13) | 1.10 (0.99–1.22) | ||
| > = 30.0 | 1.26 (1.13–1.4) | 1.22 (1.08–1.37) | ||
| 1.00 (1.15–0.87) | <0.001 | 0.96 (0.95–0.97) | <0.001 | |
| 1.73 (1.59–1.87) | <0.001 | 1.23 (1.12–1.35) | <0.001 | |
| 0.75 (0.69–0.81) | <0.001 | 0.80 (0.73–0.87) | <0.001 | |
| <0.001 | <0.001 | |||
| eGFR≤5 | 1.66 (1.43–1.92) | 1.50 (1.26–1.78) | ||
| 5<eGFR≤10 | 1.06 (0.97–1.17) | 1.11 (1.00–1.23) | ||
| 10<eGFR≤15 | 1 | 1 | ||
| 15<eGFR≤20 | 1.06 (0.88–1.28) | 1.01 (0.83–1.24) | ||
| eGFR>20 | 1.41 (1.06–1.86) | 1.36 (1.00–1.84) | ||
| <0.001 | 0.102 | |||
| In center | 1 | 1 | ||
| Satellite unit | 0.41 (0.32–0.53) | 0.72 (0.55–0.95) | ||
| Self-dialysis | 0.43 (0.33–0.57) | 0.81 (0.61–1.09) | ||
| <0.001 | 0.077 | |||
| Public university | 1 | 1 | ||
| Public non-university | 0.74 (0.67–0.82) | 0.91 (0.82–1.02) | ||
| Private for-profit | 0.67 (0.61–0.74) | 0.78 (0.70–0.88) | ||
| Private not-for-profit | 0.41 (0.36–0.46) | 0.78 (0.67–0.91) | ||
| 0.98 (0.98–0.98) | <0.001 | 0.98 (0.98–0.99) | <0.001 | |
| <0.001 | <0.001 | |||
| [0,1] | 9.25 (8.17–10.47) | 8.75 (7.68–9.96) | ||
| [1,3] | 1.66 (1.46–1.89) | 1.53 (1.34–1.75) | ||
| [3,6] | 1.14 (0.98–1.31) | 1.11 (0.96–1.29) | ||
| [6,9] | 1.05 (0.88–1.25) | 1.03 (0.86–1.23) | ||
| [9,12] | 1.06 (0.87–1.29) | 1.03 (0.84–1.27) | ||
| ≥12 | 1 | 1 | ||
a Mean number of patients with planned dialysis start through the 20 imputed data sets.
bORs adjusted for year of hemodialysis initiation and region’s annual percentage of patients with predialysis arteriovenous access creation in addition to all variables in Table 1. Abbreviations: OR: odds ratio; CI: confidence interval; ESA, erythropoiesis-stimulating agents; MDRD, Modification of Diet in Renal Disease; AV, arteriovenous.
Fig 2Prevalence and adjusted odds ratios of nonfunctional AV access at hemodialysis initiation according to timing of AV access creation and comorbidities in patients with a planned dialysis start.
N* = number of patients within time lags through the 20 imputed data sets. Analyses were adjusted for all variables in Table 1 plus year of hemodialysis initiation and the region’s annual percentage of patients with predialysis AV access. P-value of interaction between comorbidity profile and timing of AV access creation: 0.059. P-value of timing of AV access creation in both stratified models: <0.001. Abbreviations: AV, arteriovenous; ref, reference.